Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

2.670 -0.030 (-1.11%)
Streaming Delayed Price Updated: 12:12 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revance Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Proposed Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
From Revance Therapeutics, Inc.
Via Business Wire
Revance Provides Corporate Update at Investor Day
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Host Investor Day on September 19, 2023
From Revance Therapeutics, Inc.
Via Business Wire
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the Needham 22nd Annual Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.